Ken Griffin Celldex Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 49,000 shares of CLDX stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,000
Previous 83,900
41.6%
Holding current value
$1.03 Million
Previous $2.85 Million
56.56%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Wellington Management Group LLP Boston, MA8.98MShares$189 Million0.04% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.06MShares$107 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$81.9 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$79.2 Million1.82% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $987M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...